Biocardia says Japan filing work is progressing, FDA feedback on Helix is expected within six weeks, and a potential de novo submission is targeted for first quarter of 2027. It ended with $2.2 million in cash, providing runway into 2027.
BCDA · BioCardia, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Due to the factors described above, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. While we believe in the viability of our strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
BioCardia reported a $1.8 million net loss for the three months ended September 2026 and ended the quarter with $2.2 million in cash and cash equivalents, providing anticipated runway into 2027.
BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.
BioCardia completed consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), advancing the CardiAMP Cell Therapy System toward a marketing approval application in Japan. Completion does not constitute regulatory approval, and PMDA review remains outstanding.
BioCardia announced the FDA accepted its De Novo pre-submission package for marketing clearance of the Helix catheter, with substantive review and a meeting expected this quarter.
BioCardia announced the CardiAMP HF II trial design for presentation at the Heart Failure Society of America Annual Scientific Meeting 2026; FDA said the ongoing trial may support approval.
BioCardia completed its revised De Novo Pre-Submission seeking FDA approval of the Helix Catheter for agent delivery to the heart. FDA identified two marketing-clearance pathways and raised no concerns about safety data, device performance, or agent compatibility.
BioCardia targets a Q4 2026 PMDA Shonin submission for CardiAMP, which could result in market clearance by Q4 2027, and plans a Helix follow-on De Novo pre-submission this quarter.
BioCardia regained compliance with Nasdaq’s $1.00 per share minimum bid price requirement after its closing bid price remained at $1.00 per share or greater for at least 10 consecutive business days. The matter is closed, and BCDA continues trading on The Nasdaq Capital Market.